LX2931 is a small molecule compound with potential application in the treatment of diseases such as multiple sclerosis and rheumatoid arthritis.
In preclinical research, LX2931 significantly reduced inflammatory response in mice and decreased lymphocyte counts in multiple species.
“We continue to anticipate that we will file an IND for LX1031 for irritable bowel syndrome later this year,” said Arthur Sands, Lexicon's president and CEO.
Lexicon is conducting preclinical research with lead small molecule compounds that inhibit LG267, a kinase that regulates immune cell activation and affects lymphocyte proliferation. This compound may also have applications in helping cancer patients recover from chemotherapy.